A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult

British Medical Journal

Volumn 317, Issue 7158, 1998, Pages 559-565

  Towler, Bernie ^a,c   Irwig, Les ^b,c   Glasziou, Paul ^d   Kewenter, Jan ^e   Weller, David ^f   Silagy, Chris ^f  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Department of Epidemiology ^*  (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PRIORITY JOURNAL;

EID: 0032578325     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.317.7158.559     Document Type: Article

References (26)

1. Jeffs P, Coates M, Giles G, Shugg D, Threlfall T, Roder D, et al. Cancer in Australia 1989-1990 (with projections to 1995). Canberra: Australian Institute of Health and Welfare, 1996. (Cancer Series No 5.)
2. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J, eds. Cancer incidence in five continents. Vol VI. Lyon: International Agency for Research on Cancer, International Association of Cancer Registries, 1992.
3. Stewart Brown S, Farmer A. Screening could seriously damage your health. Decisions to screen must take account of the social and psychological costs. BMJ 1997;314:533-4.
4. Mulrow CD, Oxman AD, eds. Critical appraisal of studies. Cochrane Collaboration handbook [updated 9 December 1996]. Section 6. In: The Cochrane Library [database on disc and CD ROM]. Cochrane Collaboration; Issue I. Oxford: Update Software; 1997. Updated quarterly.
5. Lau J. Meta-analyst version 0.991. A program for the meta-analysis of 2 by 2 tables. Boston MA: New England Medical Center, 1997.
6. Petitti DB. Meta-analysis, decision analysis and cost-effectiveness analysis: methods for quantitative synthesis in medicine. Oxford: Oxford University Press, 1994.
7. Glasziou PP. Meta-analysis adjusting for compliance: the example of screening for breast cancer. J Clin Epidemiol 1992;45:1251-6.
8. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365-71.
9. Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
10. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
11. Kewenter J, Brevinge H, Engaras B, Haglind E, Ahren C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol 1994;29:468-73.
12. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993;85:1311-8.
13. Faive J, Arveux P, Milan C, Durand G, Lamour J, Bedenne L. Participation in mass screening for colorectal cancer: results of screening and rescreening from the Burgundy study. Eur J Cancer Prev 1991;1:49-55.
14. Kewenter J, Brevinge H. Endoscopic and surgical complications of work-up in screening for colorectal cancer. Dis Colon Rectum 1996; 39:676-80.
15. Gilbertson VA, Church TR, Grewe FJ, Mandel JS, McHugh RB, Schuman LM, et al. The design of a study to assess occult-blood screening for colon cancer. J Chron Dis 1980;33:107-44.
16. Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27 700 subjects. Cancer 1988;62:645-51.
17. Hardcastle JD, Thomas WM, Chamberlain J, Pye G, Sheffield J, James PD, et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107 349 subjects. Lancet 1989;i:1160-4.
18. Kronborg O, Fenger C, Olsen J, Bech K, Sondergaard O. Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen, Denmark. Scand J Gastroenterol 1989;24:599-606.
19. Church TR, Mandel JS, Bond JH, Ederer F, Snover DC, Bradley GM, et al. Colon cancer control study: status and current issues. In: Miller AB, Chamberlain J, Day NF, Hakama M, Prorok PD, eds. Cancer screening, Cambridge: Cambridge University Press, 1991:83-105.
20. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ 1995;311:1356-9.
21. Guidelines for early detection, screening and surveillance for colorectal cancer. 2nd ed. Sydney: Australian Gastroenterology Institute, Australian Cancer Society, 1994.
22. Lynch HT, Rozen P, Shuelke GS. Hereditary colon cancer: polyposis and non-polyposis variants. Cancer 1985;35:95-115.
23. Dunlop MG. Screening for large bowel cancer in individuals with a family history of colorectal cancer. Br J Surg 1992;79:488-94.
24. St John DJ, McDermott FT, Hopper JL, Debney EA, Johnson WR, Hughes ESR. Cancer risk in relatives with common colorectal cancer. Ann Intern Med 1993;118:785-90.
25. Castiglione G, Zappa M, Grazzini G, Mazzotta A, Biagini M, Salvadori P, et al. Immunochemical versus guaiac faecal occult blood tests in a population based screening program for colorectal cancer. Br J Cancer 1996; 74:141-4.
26. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of faecal occult blood tests for colorectal cancer screening. N Engl J Med 1996; 334:155-9.